4.4.1.20 2-benzoyl-5-(5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl)benzoic acid i.e. TK04, competitive mode of binding versus leukotriene A4 197438 4.4.1.20 2-benzoyl-5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]benzoic acid potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells 226084 4.4.1.20 2-methyl-5-(1-methylethyl)cyclohexa-2,5-diene-1,4-dione - 59190 4.4.1.20 5-[5-[(4-chlorophenyl)(cyclopropylmethyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid compound at 6 mg/kg body weight reduces LTE4 levels in peritoneal lavage fluid by 88%and significantly decreases vascular permeability in vivo. Potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells 226086 4.4.1.20 5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid tandem benzophenone amino pyridine inhibitor 226085 4.4.1.20 5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells 226085 4.4.1.20 aspirin blocks the STAT6-dependent interleukin-4-inducible expression of LTC4S 3100 4.4.1.20 bovine serum albumin 5 mg, 45% inhibition 274 4.4.1.20 Co2+ - 23 4.4.1.20 cysteinyl-leukotriene - 129863 4.4.1.20 diethylcarbamazine IC50: 0.05 mM 51622 4.4.1.20 estrone-3-sulfate IC50: 1.9 mM 51116 4.4.1.20 hexylglutathione IC50: 1.4 mM 22115 4.4.1.20 hexylglutathione - 22115 4.4.1.20 hexylglutathione S-hexylglutathione 22115 4.4.1.20 indomethacin IC50: 1.0 mM 546 4.4.1.20 indomethacin poor inhibitor 546 4.4.1.20 KCl 0.5 mM, about 25% inhibition 79 4.4.1.20 L-699,333 i.e. 2,[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]ethoxy]butanoic acid, reversible, competitive against glutathione and non-competitive against leukotriene A4 113718 4.4.1.20 leukotriene A4 substrate inhibition 807 4.4.1.20 leukotriene C2 IC50: 0.0011 mM 33188 4.4.1.20 leukotriene C4 end product inhibition 2274 4.4.1.20 leukotriene C4 IC50: 0.0021 mM, inhibits reaction with leukotriene C4 methyl ester 2274 4.4.1.20 leukotriene C4 leukotriene C4 accumulation inhibits LTC4 synthase activity 2274 4.4.1.20 leukotriene D4 - 6548 4.4.1.20 leukotriene E4 - 20769 4.4.1.20 MK-0591 - 109732 4.4.1.20 MK-886 - 2906 4.4.1.20 MK-886 IC50: 0.0027 mM 2906 4.4.1.20 MK-886 IC50: 0.0031 mM 2906 4.4.1.20 additional information cell treatment with ERK 1/2 specific inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) blocks LTC4S expression, pyrrolidine dithiocarbamate inhibits reactive oxygen species generation and NF-?B activation, which in turn blocks LTC4S expression 2 4.4.1.20 N-ethylmaleimide inhibits the recombinant enzyme 49 4.4.1.20 NaCl 0.5 mM, about 25% inhibition 42 4.4.1.20 NEM IC50: 0.02 mM 89 4.4.1.20 NEM IC50: 0.018 mM 89 4.4.1.20 NEM - 89 4.4.1.20 p-aminohippuric acid IC50: 0.26 mM 51856 4.4.1.20 probenecid IC50: 17 mM 3131 4.4.1.20 Rose bengal IC50: 0.05 mM 1331 4.4.1.20 sodium nitroprusside in hepatic ischemia-reperfusion injured rats 1483 4.4.1.20 Sulfobromophthalein IC50: 0.06 mM 6595 4.4.1.20 Triphenyltin chloride poor inhibitor 3847 4.4.1.20 Tumor necrosis factor alpha - 2773 4.4.1.20 zymosan increase in LTC4S activity during differentiation of monocytic Mono Mac 6 cells by presence of leukotriene A4 is reduced by 80% in the presence of zymosan. Treatment with Zymosan for 48 h similarly attenuates LTC4S activity of primary human monocyte-derived macrophages and dendritic cells 34378